Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16–50 years by Kennedy, Nicholas A. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical utility and diagnostic accuracy of faecal calprotectin for
IBD at first presentation to gastroenterology services in adults
aged 16–50 years
Citation for published version:
Kennedy, NA, Clark, A, Walkden, A, Chang, JCW, FascI-spurio, F, Muscat, M, Gordon, BW, Kingstone, K,
Satsangi, J, Arnott, IDR & Lees, CW 2014, 'Clinical utility and diagnostic accuracy of faecal calprotectin for
IBD at first presentation to gastroenterology services in adults aged 16–50 years' Journal of Crohn's and
Colitis, vol. 9, no. 1, pp. 41-9. DOI: 10.1016/j.crohns.2014.07.005
Digital Object Identifier (DOI):
10.1016/j.crohns.2014.07.005
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Crohn's and Colitis
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
ScienceDirect
Journal of Crohn's and Colitis (2014) xx, xxx–xxx
CROHNS-01044; No of Pages 9Clinical utility and diagnostic accuracy
of faecal calprotectin for IBD at first
presentation to gastroenterology
services in adults aged 16–50 years
Nicholas A. Kennedy a,1,2, Annalie Clark a,1,2, Andrew Walkden a,1,2,
Jeff C.W. Chang a,2, Federica Fascí-Spurio a,2, Martina Muscat a,2,
Brydon W. Gordon b,2, Kathleen Kingstone b,2, Jack Satsangi a,2,
Ian D.R. Arnott a,2, Charlie W. Lees a,⁎,2a Gastrointestinal Unit, Western General Hospital, Edinburgh, UK
b Department of Clinical Biochemistry, Western General Hospital, Edinburgh, UKReceived 3 February 2014; received in revised form 2 July 2014; accepted 11 July 2014Abbreviations: AUC, area under the
calprotectin; IBD, inflammatory bowel
Institute of Clinical Excellence; NPV, n
colitis.
⁎ Corresponding author at: Gastrointe
537 1758; fax: +44 131 537 1007.
E-mail address: charlie.lees@ed.ac
1 These authors contributed equally
2 All authors represent the Gastroent
http://dx.doi.org/10.1016/j.crohns.20
1873-9946/© 2014 European Crohn's an
Please cite this article as: Kennedy N
gastroenterology services in adults agKEYWORDS
Crohn's disease;
Ulcerative colitis;
Inflammatory bowel
disease;
Faecal calprotectin;
Diagnostic test;
Sensitivity
Abstract
Background: Distinguishing inflammatory bowel disease (IBD) from functional gastrointestinal
(GI) disease remains an important issue for gastroenterologists and primary care physicians, and
may be difficult on the basis of symptoms alone. Faecal calprotectin (FC) is a surrogate marker
for intestinal inflammation but not cancer.
Aim: This large retrospective study aimed to determine the most effective use of FC in patients
aged 16–50 presenting with GI symptoms.
Methods: FC results were obtained for patients presenting to the GI clinics in Edinburgh between
2005 and 2009 from the Edinburgh Faecal Calprotectin Registry containing FCs from N16,000
patients. Case notes were interrogated to identify demographics, subsequent investigations and
diagnoses.curve; CD, Crohn's disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FC, faecal
disease; IBDU, inflammatory bowel disease unclassified; NHS, National Health Service; NICE, National
egative predictive value; PPV, positive predictive value; ROC, receiver operating curve; UC, ulcerative
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gastroenterology services in adults agResults: 895 patients were included in the main analysis, 65% female and with a median age of
33 years. 10.2% were diagnosed with IBD, 7.3% with another GI condition associated with an
abnormal GI tract and 63.2% had functional GI disease. Median FC in these three groups were
1251, 50 and 20 μg/g (p b 0.0001). On ROC analysis, the AUC for FC as a predictor of IBD vs.
functional disease was 0.97. Using a threshold of ≥50 μg/g for IBD vs. functional disease yielded
a sensitivity of 0.97, specificity of 0.74, positive predictive value of 0.37 and negative predictive
value of 0.99. Combined with alarm symptoms, the sensitivity was 1.00.
Conclusions: Implementation of FC in the initial diagnostic workup of young patients with GI
symptoms, particularly those without alarm symptoms, is highly accurate in the exclusion of IBD,
and can provide reassurance to patients and physicians.
© 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.A, et al, Clinical utility and dia
ed 16–50 years, J Crohns Coliti1. Introduction
The relatively non-specific clinical manifestations of gastroin-
testinal disease can make it difficult for clinicians to distinguish
between functional and organic intestinal disease, especially
in patients presenting without rectal bleeding or systemic
upset.1,2 The gold standard for identifying bowel inflamma-
tion, colonoscopy and histology, is an expensive and invasive
procedure. Although attitudes to clinical targets have changed,
endoscopic services are limited in many countries and a
non-invasive tool to select individuals for early referral and
investigations would enable the most cost effective use of
resources.
Faecal calprotectin (FC), a 36.5 kDa calcium-binding cyto-
solic protein found in neutrophils, is increasingly being used in
clinical practice as a surrogate marker for intestinal inflamma-
tion. FC correlates with faecal excretion of white cells and a
number of studies have demonstrated that FC is significantly
elevated in the stool of patients with active inflammatory
bowel disease (IBD) compared to control groups.3–6 There is a
large amount of existing literature relating to FC and its use in
differentiating IBD and irritable bowel syndrome (IBS). Howev-
er, the majority of these studies use data obtained from
patients with a pre-existing diagnosis of IBD and IBS. Few
studies assess the use of FC in undiagnosed populations; those
that do analyze small sample sizes.3,5–9 FC is described by the
British Society for Gastroenterology IBD guidelines as accurate
in detecting colonic inflammation, and a NICE review was
completed in October 2013.10,11 The systematic review that
has been produced as part of this assessment reported that
‘calprotectin testing will lead to considerable savings to
the NHS, as well as the avoidance of an unpleasant invasive
procedure in people whose symptoms are due to IBS.’12
The current recommended upper limit of FC in the faeces
of healthy individuals is 50 μg/g. A meta-analysis of adult
patients has previously given sensitivity of 95% and a specificity
of 91% when using a 50 μg/g cut-off threshold for differenti-
ating IBD from healthy controls.13 Amore recent meta-analysis
of prospective studies using patients with suspected IBD found
the pooled sensitivity and specificity of FC to be 93% and 96%
respectively, although this analysis used studies with variable
cut off values ranging from 24 to 150 μg/g.14 Importantly, FC is
a poor test for colorectal cancer with a sensitivity and
specificity of 36% and 71% respectively.13 However FC could
potentially be used in clinical practice to identify young adult
patients who require further invasive investigation to exclude
intestinal inflammation. When used in the correct clinical
scenario, with no alarm symptoms present, a negative FCgno
s (2result could be highly suggestive of an absence of organic
gastrointestinal disease, thus usually avoiding the need
for invasive investigation. Patients over the age of 50 years
presenting with lower GI symptoms will require colonoscopy to
exclude colorectal cancer.
Since 2005 a reliable FC assay has been available in the
biochemistry department at the Western General Hospital,
Edinburgh. More than 8000 assays had been performed by
2008. Our clinical practice has evolved to utilise FC values in
two main areas. First, FC has been used to monitor disease
activity in patients with established IBD; second, to exclude
IBD in patients presenting to the out-patient clinic with
lower GI upset. As confidence in the utility of FC has grown,
we have tended in recent years to avoid invasive endoscopic
and radiological investigation in young adult patients with a
negative FC (b50 μg/g) and no alarm symptoms.
This study aimed to determine the most effective use of
FC in the diagnosis of GI disease in patients with no prior
known GI disease, at the first presentation to GI services. We
assessed how FC can be used as a non-invasive tool to
aid referral to GI services, and how this improves cost
effectiveness of resource allocation through reduction of
unnecessary colonoscopies. Comparison was made against
other serummarkers to determine the optimal initial diagnostic
workup of patients aged 16–50 years.
2. Methods
2.1. Patient population
Patient data were analysed from two large teaching
hospitals within the same healthcare board (NHS Lothian):
Western General Hospital (WGH), Edinburgh, and the Royal
Infirmary Edinburgh (RIE). These were identified using the
Edinburgh Faecal Calprotectin Register (EFCR), a record
kept by the Biochemistry department at WGH. The EFCR
contains the name, patient I.D., date of birth, referring
hospital/department, and FC concentration for all of the
samples analysed.
2.2. Derivation of cohort
The EFCR contains the data of 22,204 FC samples from
16,267 patients (Fig. 1). Patients were identified who had
had their first FC between January 2005 and April 2009 to
allow sufficient follow-up time to pick up cases of latent IBD.
1544 patients were aged 50 or under and had at least onestic accuracy of faecal calprotectin for IBD at first presentation to
014), http://dx.doi.org/10.1016/j.crohns.2014.07.005
Figure 1 Derivation of the cohort.
3Calprotectin in first presentation to GI servicessample originating from the WGH or RIE from the index
period. Where multiple FC samples were listed for the
same patient, the initial FC value from the patient's first
presentation was included in all analyses. Subjects were
excluded from the study if they had a confirmed GI diagnosis
at time of sample (n = 247) or if they had already started
treatment for presumed IBD (n = 14).
For the primary analysis, patients suffering from severe
intercurrent illnesses (n = 19) were excluded as were patients
receiving NSAID or aspirin therapy (n = 52), aminosalicylates
and/or corticosteroids (n = 2), leaving 895 patients in the final
cohort.2.3. FC assay technique
FC was measured in a faecal extract using a standard
enzyme-linked immunosorbent assay (ELISA) technique as
previously described (Calpro AS, Norway).15 Faecal extract
was added to a microtitre plate pre-coated with polyclonal
antibodies to FC. Bound FC was detected using an alkaline
phosphatase labelled human antibody to FC and quantified by
comparison with a known standard preparation (numerical
values given between 20 and 2500 μg/g). This assay was
performed in the Department of Clinical Biochemistry at the
Western General Hospital, Edinburgh. The reported assay
precision for the calprotectin ELISA is a coefficient of variation
(CV) of less than 6%. When including the faecal extraction
step, the CV for the entire assay has been estimated to be less
than 10% (unpublished data; 2014 email from Susan Walker,
Department of Clinical Biochemistry, Western General Hospi-
tal, Edinburgh).2.4. Data collection
Data was collected retrospectively by review of electronic
patient records and recorded on a standardised data collection
form. The electronic patient record system (Trak, Intersystems,
Cambridge MA, USA) logs all patient contacts with secondary
care (throughout NHS Lothian), including all endoscopic and
radiological investigations, clinic appointments and hospital
admissions. This data was then cross-referenced with other
hospital electronic databases that store clinic letters andPlease cite this article as: Kennedy NA, et al, Clinical utility and diagno
gastroenterology services in adults aged 16–50 years, J Crohns Colitis (2laboratory results in order to ensure the maximum retrieval
and accuracy of data. Patients were followed up until at least
three years after first presentation using Trak, ensuring all
re-presentations and subsequent diagnoses were noted.
Parameters recorded were: age, gender, FC level and
date of sample, presenting complaints (bloody diarrhoea,
watery diarrhoea, rectal bleeding, constipation, abdominal
pain, weight loss, flatulence/bloating, vomiting, dyspepsia,
fatigue, possible extraintestinal manifestations, other),
past medical history, family history (ulcerative colitis (UC),
Crohn's disease (CD), IBD unclassified (IBDU), coeliac disease,
colon cancer), smoking history (current at time of FC, ex- or
never), drug history (including NSAIDs, antibiotics, laxatives,
opioids, immunosuppresants, loperamide, aminosalicylates,
acetaminophen, aspirin, corticosteroids), investigations per-
formed (stool culture, colonoscopy, flexible sigmoidoscopy,
upper GI endoscopy, abdominal ultrasound scan, abdominal
X-ray, small bowel MRI, abdominal/pelvic CT, barium enema,
barium follow-through, capsule endoscopy and radio-labelled
white cell scan) and blood results (full blood count, liver
function tests, erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), albumin, hematinics (ferritin, vitamin
B12 and serum folate), thyroid function tests, glucose, 7
alphahydroxycholestenone and anti-tissue transglutaminase
IgA titre). Rectal bleeding, bloody diarrhoea, nocturnal
symptoms, weight loss and anaemia were grouped as “alarm
symptoms”. Where a laboratory test was reported as greater
or less than a threshold, for statistical purposes it was assigned
to one more or one less than the threshold respectively.
Any investigations performed were recorded as normal,
abnormal or incomplete. “Abnormal” endoscopy findings
included mucosal abnormalities, such as histologically proven
malignancies and inflammation. The normal group includes
those where no abnormalities were found as well as non-
adenomatous polyps and haemorrhoids.2.5. Diagnosis
Diagnosis was recorded as had been stated in the clinical
notes. The Lennard-Jones criteria were used to diagnose IBD
and the Montreal criteria to classify clinical phenotypes.16,17
The ROME III criteria were used to classify patients diagnosed
with IBS.18 In cases where a diagnosis had not been recorded in
the clinical notes, anonymised patient's notes were reviewed
independently by two gastroenterologists blinded to the FC
level (CWL and IDRA). Organic GI diagnoses were grouped as
IBD, ‘abnormal gastrointestinal (GI) tract’ where a diagnosis
would be expected to demonstrate a macroscopically abnor-
mal GI tract and other GI where bidirectional endoscopy and
capsule endoscopy would be expected to be normal. Details
can be seen in Table S1.
Patients with a definitive organic diagnosis or who had
undergone full colonoscopy (n = 467) were censored at the
time of initial case note review. Those cases where an organic
diagnosis was not made at the time of the FC or where no
colonoscopy had been performed (n = 428) were reviewed in
the last quarter of 2012 to ensure that no further cases of IBD
or other significant GI pathology had been missed. Patients
whose symptoms resolved spontaneously, who did not require
further investigation and who did not re-present to hospital
with GI symptoms were classified as ‘symptoms resolved.’stic accuracy of faecal calprotectin for IBD at first presentation to
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Table 1 Demographics of study population.
Variable All
n (%) or median (IQR)
Primary analysis cohort
n (%) or median (IQR)
Sex Female 627/968 (64.8%) 581/895 (64.9%)
Age at calprotectin/years 33.3 (25.7–41.0) 33.1 (25.6–40.7)
Smoking status at calprotectin Current 204/641 (31.8%) 183/594 (30.8%)
Ex 72/641 (11.2%) 68/594 (11.4%)
Never 365/641 (56.9%) 343/594 (57.7%)
Unknown 327/968 (33.8%) 301/895 (33.6%)
Drugs at calprotectin NSAIDS 22/769 (2.9%) 0/701 (0.0%)
Antibiotics 50/769 (6.5%) 0/701 (0.0%)
Laxatives 16/769 (2.1%) 12/701 (1.7%)
Opiates 39/769 (5.1%) 38/701 (5.4%)
Immunosuppressants 82/769 (10.7%) 61/701 (8.7%)
Loperamide 6/769 (0.8%) 2/701 (0.3%)
Aminosalicylates 47/769 (6.1%) 42/701 (6.0%)
Acetaminophen 1/769 (0.1%) 0/701 (0.0%)
Aspirin 73/769 (9.5%) 52/701 (7.4%)
Corticosteroids 2/769 (0.3%) 0/701 (0.0%)
Unknown 199/968 (20.6%) 194/895 (21.7%)
Family history None a 862/968 (89.0%) 794/895 (88.7%)
UC 22/968 (2.3%) 21/895 (2.3%)
CD 27/968 (2.8%) 26/895 (2.9%)
IBDU 63/968 (6.5%) 60/895 (6.7%)
Coeliac disease 11/968 (1.1%) 11/895 (1.2%)
Colon cancer 14/968 (1.4%) 13/895 (1.5%)
Previous medical history None a 920/968 (95.0%) 868/895 (97.0%)
Inflammatory disease (non-gastrointestinal) 30/968 (3.1%) 24/895 (2.7%)
Ankylosing spondylitis 30/968 (3.1%) 24/895 (2.7%)
HIV 3/968 (0.3%) 2/895 (0.2%)
Alcoholic liver disease 9/968 (0.9%) 0/895 (0.0%)
Severe intercurrent illness 6/968 (0.6%) 1/895 (0.1%)
NSAIDS: non-steroidal anti-inflammatory drugs; UC: ulcerative colitis; CD: Crohn's disease; IBDU: inflammatory bowel disease unclassified.
a It has been assumed for this table that in the absence of any recorded previous medical history or family history in the patient records
that there is none.
4 N.A. Kennedy et al.Those who were lost to follow-up without a definitive
diagnosis were classed as ‘lost to follow-up’.
The main comparisons have been made in those with
functional disease vs. those with IBD or another condition
associatedwith an abnormal tract, since these are the patients
in whom endoscopy would be a potentially useful test.
2.6. Cost analysis
Potential cost savings were calculated using 2012 tariff
prices quoted by the Department of Health.19 One colonos-
copy with biopsies in a patient aged 19 years or older was
stated to cost £563, while a flexible sigmoidoscopy plus
biopsy cost £360. The in-house processing cost of a single FC
assay at WGH in 2008 was £24.47.2.7. Statistical analysis
Statistical analyses of functional vs. organic groups and
functional vs. IBD groups were performed. Medians and inter-
quartile range are provided. Mann–Whitney U, Kruskal–Wallis,
chi-squared and Fisher's exact tests were used to determine
statistical significance. Receiver operating characteristic (ROC)Please cite this article as: Kennedy NA, et al, Clinical utility and diagno
gastroenterology services in adults aged 16–50 years, J Crohns Colitis (2curves were used to determine the best cut off point for FC
when predicting organic disease and IBD. Comparison of area
under the curve (AUC) was performed using the Delong
and bootstrap methods. Positive predictive values (PPV) and
negative predictive values (NPV) were calculated. Pre-test
probabilities were calculated using all individuals regardless of
FC concentration. Post-test probabilities were calculated with
respect to different thresholds of FC.
A two-tailed p-value of less than 0.05 was considered
significant. Confidence intervals for sensitivity and specificity
were calculated using the method described by Newcombe
with continuity correction.20 Confidence intervals for likeli-
hood ratios were calculated using the method described by
Simel et al.21 Statistical analyses were performed using R 3.0.1
(R Foundation for Statistical Computing, Vienna, Austria).3. Results
3.1. Demographics
64.9% of patients were female, and the median age (interquar-
tile range) at the time of FC was 33.1 years (25.6–40.7)
(Table 1). 566/895 (63.2%) of patients were diagnosed with astic accuracy of faecal calprotectin for IBD at first presentation to
014), http://dx.doi.org/10.1016/j.crohns.2014.07.005
Table 2 Faecal calprotectin, age and time from calprotectin to diagnosis by diagnostic category.
Diagnosis category n (%) % female Median
age/years
(IQR)
Median faecal
calprotectin/μg/g
(IQR)
Median
time from
calprotectin to
diagnosis/days
(IQR)
Functional 566/895 (63.2%) 68.40% 32.7 (26.0–40.3) 20 (b20–50.0) 95 (40–190)
IBD 91/895 (10.2%) 51.60% 29.8 (24.2–39.7) 1251 (532.5–2325.0) 7 (0–64)
Abnormal GI tract 65/895 (7.3%) 53.80% 37.7 (26.1–44.4) 50 (20.0–145.0) 92 (41–206)
Other GI 63/895 (7.0%) 65.10% 35 (27.0–42.8) 20 (b20–70.0) 92 (35–153)
Other organic 32/895 (3.6%) 68.80% 31 (25.3–41.4) 22.5 (b20–86.2) 106 (34–192)
Lost to Fup 29/895 (3.2%) 62.10% 35.8 (26.5–43.2) 135 (35.0–325.0)
None 1/895 (0.1%) 100.00% 20.8 1825
Symptoms resolved —
no GI pathology
48/895 (5.4%) 62.50% 34.3 (25.3–42.7) 35 (b20–76.2)
5Calprotectin in first presentation to GI servicesfunctional disorder (Table 2). 91/895 (10.2%) were diagnosed
with IBD, while a further 58 (7.3%) had conditions associated
with an abnormal gastrointestinal tract. 63 patients (7.0%)
had other miscellaneous gastrointestinal disorders. 78 patients
(8.7%) did not have a final diagnosis, of whom 48 had complete
symptomatic resolution and have not re-presented in≥3 years,
one has had further presentations with abdominal pain without
a diagnosis while the remainder were lost to follow-up.
3.2. FC and demographic variables
FC was not significantly associated with age (p = 0.21), sex
(p = 0.18) or current smoking (p = 0.80).
3.3. FC and other clinical parameters assessed by
final diagnosis
FC was significantly higher in patients diagnosed with IBD
(median FC 1251 μg/g, IQR 532–2325 μg/g) than those with
other conditions associated with an abnormal gastrointesti-
nal tract (median FC 50 μg/g, IQR 20–145 μg/g) or with a
functional diagnosis (median FC 20 μg/g, IQR b 20–50 μg/g)
(p ≤ 0.0001 in each case, see Fig. 2).
3.4. FC in patients taking non-steroidal
anti-inflammatories (NSAIDs)
Patients taking NSAIDs or aspirin were excluded from the
primary analysis. In patients with a functional diagnosis, the
FC was significantly higher in those taking NSAIDs or aspirin
when compared with those on neither drug (median FC
52 μg/g [IQR b 20–181 μg/g] vs. 20 μg/g [IQR b 20–50 μg/g],
p = 0.001).
3.5. FC in patients with IBD
Of the 91 patients ultimately diagnosed with IBD, 40 (44%) had
CD, 41 (45%) had UC and 10 (11%) had IBDU. There was no
significant difference in FC between the three subtypes of IBD
(p = 0.56). Within the groupwith CD, there were 10 (25%) with
L1 (ileal) disease, including one patient with L1 + 4, 18 (45%)
with L2 (colonic) disease and 12 (30%) with L3 (ileocolonic)Please cite this article as: Kennedy NA, et al, Clinical utility and diagno
gastroenterology services in adults aged 16–50 years, J Crohns Colitis (2disease. FC was significantly higher in those with L2 or
L3 disease, with a median (IQR) of 1280 (714–2295) μg/g
than in those with L1 disease where median (IQR) FC was 495
(288–822) μg/g (p = 0.009) (Supplementary Fig. 1).
Within the group with UC, there were 3 (7%) with E1
disease (proctitis), 12 (29%) with E2 disease (left-sided colitis)
and 21 (51%)with E3 disease (extensive colitis). In the remaining
5 patients, the disease extended beyond the point of insertion
of the sigmoidoscope and complete staging of extent was
not achieved during the initial diagnostic period. There
was no significant difference in FC by disease extent when
those without complete staging were excluded (p = 0.25 by
Kruskal–Wallis test; Supplementary Fig. 2).
Across all patients diagnosed with IBD, there was no
significant association between time to diagnosis and faecal
calprotectin.
3.6. Diagnostic accuracy of FC compared to other
clinical parameters
Receiver operating characteristic (ROC) analysis revealed an
area under the curve (AUC) for FC of 0.85 for prediction
of conditions with an abnormal GI tract (including IBD) vs.
functional disease, and 0.97 for prediction of IBD vs. functional
disease (Fig. 3). This was significantly higher than that seen for
CRP, albumin, ESR or white cell count in both cases (p b 0.001
for all comparisons). The sensitivities, specificities, and positive
and negative predictive values for faecal calprotectin can be
seen in Table 3 at different thresholds. Summaries of the
number of available tests, medians and interquartile ranges for
each parameter can be seen in Supplementary Table S2.
3.7. Synergistic effect of FC sampling and alarm
symptoms
Alarm symptoms were present in 25% (140/566) of those
ultimately diagnosed with functional disease, 86% (78/91) of
those diagnosed with IBD and 54% (35/65) of those diagnosed
with another condition associated with an abnormal GI tract
(p b 0.0001). The positive predictive value of alarm symp-
toms for IBD or an abnormal GI tract vs. functional disease
was 0.45 (95% CI 0.38–0.51), and the negative predictive
value was 0.91 (0.88–0.93) with a sensitivity of 0.72 (0.65–stic accuracy of faecal calprotectin for IBD at first presentation to
014), http://dx.doi.org/10.1016/j.crohns.2014.07.005
Figure 2 Box plot showing difference in faecal calprotectin
between patients with functional diagnoses and those with IBD
and other conditions associated with an abnormal GI tract.
6 N.A. Kennedy et al.0.79) and specificity of 0.75 (0.71–0.79). For prediction of
IBD vs. functional disease, the PPV was 0.36 (0.29–0.43) and
NPVwas 0.97 (0.95–0.98), with a sensitivity of 0.86 (0.76–0.92)
and specificity of 0.75 (0.71–0.79).
As can be seen in Table 4, FC is helpful in improving the
prediction of an abnormal GI tract or IBD compared with
alarm symptoms alone. Within the cohort with functional
disease or an abnormal GI tract, none of the 329 patients
with no alarm symptoms and a FC of b50 μg/g was found
to have IBD, while 11/36 (31%) of patients with no alarm
symptoms and a FC of ≥200 were found to have IBD.A
Figure 3 Receiver operating characteristic curves for calprotec
inflammatory bowel disease (IBD) or abnormal gastrointestinal tract ve
Please cite this article as: Kennedy NA, et al, Clinical utility and diagno
gastroenterology services in adults aged 16–50 years, J Crohns Colitis (2Thirteen patients had no alarm symptoms and a FC of
b50 μg/g, but were found to have a disease associated with
an abnormal GI tract. These were 1 case of appendicitis, 1
coeliac disease, 3 with colonic adenomatous polyps, 1 with
diverticulosis, 3 with GI infections (1 Fasciola hepatica, 1
giardiasis, 1 presumed infection with response to metroni-
dazole), 2 with gastro-oesophageal reflux disease and 2
non-specific bowel inflammation. One of these patients with
non-specific bowel inflammation was initially thought to have
CD but had non-specific changes on her index colonoscopic
biopsies and subsequently normal colonoscopy and biopsies.
3.8. Multivariable analysis
Multiple logistic regression analysis of predictors of IBD vs.
functional disease showed that elevated FC, elevated CRP,
male sex, alarm symptoms and albumin were independently
significant. Age at FC and white cell count were not (Table 5).
Comparing different strategies of investigation (Table 6)
demonstrated that FC alone provided the optimum specificity
for both IBD vs. functional disease and IBD or abnormal GI tract
vs. functional disease. The optimal combination of sensitivity
and specificity was attained using the approach of alarm
symptoms or FC ≥ 50 μg/g. Sensitivity and specificity for IBD
vs. functional disease were 1.00 and 0.54 with this strategy,
while for IBD or abnormal GI tract vs. functional disease they
were 0.96 and 0.55. Adding CRP to this combination had
minimal effect on sensitivity, while reducing specificity.
3.9. Low FC in patients diagnosed with inflammatory
bowel disease
Three patients had a low FC (b50 μg/g) and were diagnosed
with inflammatory bowel disease. All three had alarmB
tin, CRP, albumin, ESR and white cell count as predictors of
rsus functional disease (A) and IBD versus functional disease (B).
stic accuracy of faecal calprotectin for IBD at first presentation to
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Table 3 Diagnostic accuracy of fecal calprotectin at different thresholds
PPV: positive predictive value; NPV: negative predictive value; PLR: positive likelihood ratio;
CI: confidence interval.
Threshold fecal
calprotectin (μg/g)
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV (95% CI) NPV (95% CI) PLR (95% CI)
A: Inflammatory bowel disease (IBD) or abnormal GI tract vs. functional disease
20 0.89 (0.83–0.93) 0.49 (0.44–0.53) 0.32 (0.28–0.37) 0.94 (0.91–0.96) 1.73 (1.57–1.91)
50 0.79 (0.71–0.85) 0.74 (0.70–0.77) 0.45 (0.39–0.52) 0.93 (0.90–0.95) 3.02 (2.57–3.54)
70 0.73 (0.65–0.80) 0.80 (0.76–0.83) 0.50 (0.44–0.57) 0.92 (0.89–0.94) 3.66 (3.03–4.43)
100 0.70 (0.62–0.77) 0.87 (0.84–0.90) 0.60 (0.52–0.67) 0.91 (0.89–0.93) 5.42 (4.27–6.87)
B: IBD vs. functional disease
20 0.99 (0.93–1.00) 0.49 (0.44–0.53) 0.24 (0.20–0.28) 1.00 (0.98–1.00) 1.92 (1.77–2.09)
50 0.97 (0.90–0.99) 0.74 (0.70–0.77) 0.37 (0.31–0.44) 0.99 (0.98–1.00) 3.70 (3.20–4.27)
70 0.97 (0.90–0.99) 0.80 (0.76–0.83) 0.44 (0.37–0.51) 0.99 (0.98–1.00) 4.84 (4.09–5.74)
100 0.96 (0.89–0.99) 0.87 (0.84–0.90) 0.54 (0.46–0.62) 0.99 (0.98–1.00) 7.41 (5.96–9.22)
7Calprotectin in first presentation to GI servicessymptoms (two had blood in their stool and one had weight
loss). Two of these patients were diagnosed with ulcerative
proctitis which has not extended further in N4 years of
follow-up. One had mild terminal ileal CD with no subse-
quent progression.
3.10. Cost effectiveness of FC: reducing the number
of invasive investigations
Between 2005 and 2008, our practice evolved with increas-
ing use of FC and reduction in the percentage of these
patients subsequently undergoing invasive investigation. In
the 2005, 63 patients underwent stool analysis for FC with
84.1% of them undergoing either sigmoidoscopy or colonos-
copy. In 2008, 409 patients had stool sent for FC with 56.7%
subsequently undergoing invasive investigation (Table S3).
Over the study period, 581/895 (64.9%) patients presented
without alarm symptoms. 395 of these (68.0%) had a FC of
b50 μg/g. 150 of these patients (38%) had a subsequent
colonoscopy and 50 (13%) a flexible sigmoidoscopy, identifying
incidental adenomatous polyps in 3 patients and no other
significant pathology. If the low FC had been used to triage
these patients to a non-invasive approach, this would have
saved £88,233 over that time period.
4. Discussion
This study uses the largest, ‘real-world’ population of
undiagnosed patients to determine the best way of using FCTable 4 Pre- and post-test probabilities when combining alarm
Pre-test probability Post-te
b20
A: inflammatory bowel disease (IBD) or abnormal GI tract vs. func
Alarm symptoms 0.45 0.15
No alarm symptoms 0.09 0.03
B: IBD vs. functional disease
Alarm symptoms 0.36 0.02
No alarm symptoms 0.04 0.00
Please cite this article as: Kennedy NA, et al, Clinical utility and diagno
gastroenterology services in adults aged 16–50 years, J Crohns Colitis (2at first presentation to the GI clinic to differentiate non-
invasively between organic and functional disease. This allows
identification of those in need of efficient and effective
further investigation. Incorporating FC into the standard
work-up of patients presenting with lower GI symptoms may
potentially relieve pressure on hospital services by identifying
patients who can be managed solely in primary care.
Our findings corroborate existing data showing that FC
reliably distinguishes between patients with functional dis-
ease and IBD. Von Roon et al.'s meta-analysis of adult patients
demonstrated a sensitivity of 95% and specificity of 91% when
using a 50 μg/g cut-off point for differentiating IBD patients
from healthy controls.13 At the same cut-off, our study found
95% sensitivity but only 75% specificity. This agreement in
sensitivity reinforces the diagnostic ability of FC in identifying
patients with IBD in a large cohort of patients. The lower
specificity seen in our study may be due to the patient
population used, all of which have presented to services with
GI symptoms, unlike the healthy control population used by
Von Roon et al. Van Rheenen et al's more recent meta-analysis
of six adult studies found a pooled sensitivity and specificity of
93% and 96% respectively.22 However, inconsistent FC thresh-
olds were used in these six studies, with 47.7% of included
patients analysed using a cut-off greater than 100 μg/g, and
this may have influenced the specificity.
Both ESR and CRP are markers that are commonly used
to identify systemic inflammation in patients with IBD-like
symptoms. In accordance with previous research, we show
CRP and ESR are raised in patients with organic disease and
IBD.4,23 ROC analysis demonstrates however, that FC issymptoms and fecal calprotectin.
st probability for different values of fecal calprotectin (μg/g)
20–49 50–99 100–199 200+
tional disease
0.18 0.24 0.50 0.91
0.06 0.12 0.20 0.41
0.05 0.05 0.41 0.89
0.00 0.00 0.06 0.33
stic accuracy of faecal calprotectin for IBD at first presentation to
014), http://dx.doi.org/10.1016/j.crohns.2014.07.005
Table 5 Multiple logistic regression of predictors of inflam-
matory bowel disease vs. functional disease.
CRP: C-reactive protein.
Variable Odds ratio (95% CI) P
Fecal calprotectin
≥ 50 μg/g
65.3 (12.1–351.5) 1.1 × 10−6
Alarm symptoms 19.5 (7.9–127.5) 3.0 × 10−6
Albumin b 40 g/L 18.7 (4.1–85.4) 3.0 × 10−5
Male sex 14.1 (3.8–52.2) 7.0 × 10−5
CRP ≥ 5 g/L 6.9 (2.0–23.7) 0.002
Age at calprotectin N0.05
White cell
count N11 × 109/L
N0.05
8 N.A. Kennedy et al.superior to CRP and ESR in the diagnosis of IBD — a finding
that agrees with the recent economic report produced by the
NHS Centre for Evidence Based Purchasing.24 Furthermore, we
demonstrate that the NPV of FC in patients presenting with no
alarm symptoms is superior to the NPV of CRP for both organic
GI disease and IBD. Cost savings could be made by solely
checking FC in patients presenting with lower GI symptoms,
rather than checking CRP and ESR in these patients
One of the most clinically relevant findings from our data
is the NPV for IBD of 99.0% when a FC threshold of 50 μg/g is
used. When FC less than 50 μg/g is combined with the
absence of alarm symptoms, NPV is 100.0% for IBD. This
allows the exclusion of IBD from the differential diagnosis of
these patients. Furthermore, in patients meeting these
criteria, NPV for any GI tract abnormality is 96.1%. Of the
13 patients with no alarm symptoms and FC less than 50 μg/
g who had a diagnosis of abnormal GI tract, colonoscopy was
helpful in only four patients and these (diverticular disease
and colonic polyps) were likely incidental findings. Clinicians
can therefore be reassured that referral for colonoscopy will
not identify severe organic disease in patients in whom no
abnormalities are found in initial investigations. This finding
could potentially be applied to a primary care scenario and aid
selection of patients for colonoscopy.
With the Department of Health pricing a single colonoscopy
in adults at £563 there is great potential for FC to aid more
cost-effective decision making with regard to further investi-
gation.19 Von Rheenen et al.'s meta-analysis demonstrated that
screening with FC could reduce unnecessary colonoscopies by
67% in those suspected of having IBD.22 Similar results wereTable 6 Comparison of different strategies for identifying IBD o
IBD: inflammatory bowel disease; CRP: C-reactive protein.
Strategy IBD v
Sensi
Alarm symptoms only 0.85
CRP ≥ 5 g/L only 0.85
Faecal calprotectin (FC) ≥ 50 μg/g only 0.97
Alarm symptoms or CRP ≥ 5 g/L 0.99
Alarm symptoms or FC ≥ 50 μg/g 1.00
Alarm symptoms or CRP ≥ 5 g/L or FC ≥ 50 μg/g 1.00
Alarm symptoms or (CRP ≥ 5 g/L and FC ≥ 50 μg/g) 0.99
Please cite this article as: Kennedy NA, et al, Clinical utility and diagno
gastroenterology services in adults aged 16–50 years, J Crohns Colitis (2documented by Mindemark and colleagues, with a reduction of
colonoscopies by 50% using the FC cut off of b50 μg/g and 67%
using a FC cut off of b100 μg/g.25 During the study period of the
present study, if patients with a FC b50 μg/g and no alarm
symptoms had not undergone lower GI endoscopy there could
have been 150 fewer colonoscopies and 50 fewer flexible
sigmoidoscopies. Our data reflects real world practice, with
proportionally fewer patients being investigated by colonosco-
py as our knowledge and experience of FC increased. A reducing
trend in the numbers of those patients investigated with
colonoscopy can clearly be seen as the number of FC assays
received by the labs increase over the three years. The number
of potential colonoscopies saved quoted above may even be
more than this had our unit not been internally evaluating FC's
use in clinical practice. Furthermore, the numbers we have
analyzed only include patients who attended the GI clinic and
had a FC sample sent. These findings could be applied to all
patients who attend the GI clinic with lower GI symptoms,
potentially reducing further the number of colonoscopies and
resulting in even greater cost savings. It is important to take
into consideration that this study uses patients referred to
hospital GI services, and by virtue of this the spectrum of
symptoms seen in this population is more severe when
compared to all the patients presenting to GPs with GI
symptoms. In primary care, FC could identify the small numbers
of patients with IBD, whilst excluding its presence in a large
number of patients presenting with GI symptoms. Not only
could this streamline the referral of appropriate patients to
hospital, but it will also reduce the number of unnecessary
referrals and invasive investigations. This does, however,
require detailed pilot testing before any formal recommenda-
tions about the roll-out of FC into primary care can be made.
Moreover, it is important that FC is used in the context of a
defined protocol to ensure that it does not delay referral of
patients with alarm symptoms and that consideration is given to
possible false positive tests from aspirin and non-steroidal
inflammatory drugs.
One of the strengths of this study is that all individuals
without a definitive diagnosis or in whom a functional diagnosis
had been made without colonoscopy were re-reviewed three
years later to identify any possible latent cases of IBD or other
GI disease.
This study clarifies important, clinically relevant infor-
mation about FC. Awareness of the high negative predictive
value of FC allows clinicians to effectively exclude IBD as
a cause for gastrointestinal symptoms in patients with FCr abnormal gastrointestinal (GI) tract vs. functional disease.
s. functional IBD or abnormal GI tract vs.
functional
tivity Specificity Sensitivity Specificity
0.73 0.76 0.74
0.70 0.71 0.70
0.74 0.86 0.75
0.50 0.89 0.51
0.54 0.96 0.55
0.39 0.97 0.39
0.65 0.88 0.67
stic accuracy of faecal calprotectin for IBD at first presentation to
014), http://dx.doi.org/10.1016/j.crohns.2014.07.005
9Calprotectin in first presentation to GI serviceslevels under 50 μg/g. FC can thus be used as an adjunct to
other presenting complaints and investigations, allowing the
risk stratification of patients presenting with gastrointesti-
nal symptoms in a cost-effective manner.
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